These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30413829)

  • 1. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Kuss O; Müssig K; Burkart V; Szendroedi J; Kotzka J; Knebel B; Al-Hasani H; Roden M;
    Diabetologia; 2019 Feb; 62(2):286-291. PubMed ID: 30413829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.
    Zhou K; Yee SW; Seiser EL; van Leeuwen N; Tavendale R; Bennett AJ; Groves CJ; Coleman RL; van der Heijden AA; Beulens JW; de Keyser CE; Zaharenko L; Rotroff DM; Out M; Jablonski KA; Chen L; Javorský M; Židzik J; Levin AM; Williams LK; Dujic T; Semiz S; Kubo M; Chien HC; Maeda S; Witte JS; Wu L; Tkáč I; Kooy A; van Schaik RHN; Stehouwer CDA; Logie L; ; ; ; Sutherland C; Klovins J; Pirags V; Hofman A; Stricker BH; Motsinger-Reif AA; Wagner MJ; Innocenti F; 't Hart LM; Holman RR; McCarthy MI; Hedderson MM; Palmer CNA; Florez JC; Giacomini KM; Pearson ER
    Nat Genet; 2016 Sep; 48(9):1055-1059. PubMed ID: 27500523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Study on the Relationship between the SNP rs8192675 (C/C) Site of SLC2A2 Gene and the Hypoglycemic Effect of Metformin in Type 2 Diabetes.
    Ye W; Wang Y; Chen F; Zhao Q; Meng X; Chen J; Liu C; Zhou Y
    J Healthc Eng; 2022; 2022():3645336. PubMed ID: 35140900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes.
    Gormsen LC; Søndergaard E; Christensen NL; Brøsen K; Jessen N; Nielsen S
    Diabetologia; 2019 Jul; 62(7):1251-1256. PubMed ID: 30976851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of TCF7L2 rs7903146 variant on metformin response in patients with type 2 diabetes.
    Dujic T; Bego T; Malenica M; Velija-Asimi Z; Ahlqvist E; Groop L; Pearson ER; Causevic A; Semiz S
    Bosn J Basic Med Sci; 2019 Nov; 19(4):368-374. PubMed ID: 31070566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
    Li JH; Brenner LN; Kaur V; Figueroa K; Schroeder P; Huerta-Chagoya A; ; ; Udler MS; Leong A; Mercader JM; Florez JC
    Diabetologia; 2023 Jul; 66(7):1260-1272. PubMed ID: 37233759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of insulin sensitivity, beta-cell function and glycaemic control on initiation of second-line glucose-lowering treatment in newly diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Bobrov P; Kuss O; Müssig K; Markgraf DF; Szendroedi J; Herder C; Roden M;
    Diabetes Obes Metab; 2017 Jun; 19(6):866-873. PubMed ID: 28127851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus.
    Nasykhova YA; Barbitoff YA; Tonyan ZN; Danilova MM; Nevzorov IA; Komandresova TM; Mikhailova AA; Vasilieva TV; Glavnova OB; Yarmolinskaya MI; Sluchanko EI; Glotov AS
    Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
    Walford GA; Colomo N; Todd JN; Billings LK; Fernandez M; Chamarthi B; Warner AS; Davis J; Littleton KR; Hernandez AM; Fanelli RR; Lanier A; Barbato C; Ackerman RJ; Khan SQ; Bui R; Garber L; Stolerman ES; Moore AF; Huang C; Kaur V; Harden M; Taylor A; Chen L; Manning AK; Huang P; Wexler D; McCarthy RM; Lo J; Thomas MK; Grant RW; Goldfine A; Hudson MS; Florez JC
    PLoS One; 2015; 10(3):e0121553. PubMed ID: 25812009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
    Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
    Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin.
    Li Q; Liu F; Zheng TS; Tang JL; Lu HJ; Jia WP
    Acta Pharmacol Sin; 2010 Feb; 31(2):184-90. PubMed ID: 20139901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
    Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
    Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
    Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
    He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
    Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.